Drug-induced inflammatory rheumatisms;Rhumatismes inflammatoires induits par les médicaments

Revue du Rhumatisme (Edition Francaise)

Volumn 71, Issue 6, 2004, Pages 489-497

  Hachulla, Eric ^a   Flipo, René Marc ^a   Puisieux, François ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Arthritis; Drug induced; Iatrogene; Polyarthritis; Side effects; Systemic disease

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMPICILLIN; CHLORTALIDONE; CLOPAMIDE; CLOPIDOGREL; CORTIVAZOL; CYCLOSPORIN; ETACRYNIC ACID; ETHAMBUTOL; FLUORIDE SODIUM; FUROSEMIDE; GEMFIBROZIL; HYALURONIC ACID; ISONIAZID; MEFRUSIDE; MERCAPTOPURINE; METHISOPRINOL; MORINAMIDE; OMEPRAZOLE; PIPEROCAINE; PYRAZINAMIDE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SULFINPYRAZONE; TIENILIC ACID; UNINDEXED DRUG; XIPAMIDE; ZOXAZOLAMINE;

DRUG INDUCED DISEASE; GOUT; HUMAN; IATROGENIC DISEASE; POLYARTHRITIS; REVIEW; RHEUMATIC DISEASE;

EID: 16344381380     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2004.03.007     Document Type: Article

References (55)

1. BIAM. http//:www.biam2.org.
2. Bardin T. Fenofibrate et losartan. Ann Rheum Dis 2003;62:497-8.
3. Bardin T, Kuntz D. Gouttes induites par les médicaments. In: de Sèze S, Ryckewaert A, Kahn MF, Guérin C, editors. 1988. p. 347-51 Actualité rhumatologique 1988, Paris, Expansion Scientifique Française.
4. Sloan RW. Hyperuricemia and gout. J Fam Pract 1982;14:923-34.
5. di Fazano CS, Bertin P, Vergne P, Bonnet C, Trèves R. The pharmacological management of drug-induced rheumatic disorders. Expert Opin Pharmacother 2001;2:1623-31.
6. Vergne P, Bertin P, Bonnet C, Scotto C, Trèves R. Drug-induced rheumatic disorders. Incidence, prevention and management. Drug Safety 2000;23:279-93.
7. Bannwarth B. Drug-induced rheumatic disorders. Rev Rhum [Engl Ed] 1996;63:639-47.
8. Leopold SS, Warme W, Pettis PD, Shott S. Increased frequency of acute local reaction to intra-articular Hylan GF-20 [Synvisc] in patients receiving more than one course of treatment. J Bone Joint Surg 2002;84A:1619-23.
9. Kroesen S, Schmid W, Theiler R. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of Hylan G-F 20 [Synvisc]. Clin Rheumatol 2000;19:147-9.
10. Maillefert JF, Hirschhorn P, Pascaud F, Piroth C, Tavernier C. Acute attack of chondrocalcinosis after an intraarticular injection of hyaluronan. Rev Rhum [Engl Ed] 1997;10:593-4.
11. Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee. A report of 6 cases. J Bone J Surg 2002;84:A1142-7.
12. van der Linden PD, Sturkenboom MCJM, Herings RMC, Leufkens HGM, Stricker BHC. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324:1306-7.
13. Simonin MA, Gegout-Pottie P, Minn A, Gillet P, Netter P, Terlain B. Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice. Antimicrob Agents Chemother 1999;43:2915-21.
14. Maillefert JF, Sibilia J, Toussirot E, Vignon E, Eschard JP, Lorcerie B, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) 1999;38:978-83.
15. Hachulla E, Houvenagel E, Mingui A, Vincent G, Laine A. Reactive arthritis after hepatitis B vaccination. J Rheumatol 1990;17:1250-1.
16. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol 2002;58:301-4.
17. Buchs N, Chevrel G, Miossec P. Bacillus Calmette-Guerin induced aseptic arthritis : an experimental model of reactive arthritis. J Rheumatol 1998;25:1662-5.
18. Pardalidis NP, Papatsoris AG, Kosmaoglou EV, Georganas C. Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer. Clin Rheumatol 2002;21:536-7.
19. Mas AJ, Romera M, Valverde Garcia JM. Articular manifestations after the administration of intravesical BCG. J Bone Spine 2002;69: 92-8.
20. Pancaldi P, Van Linthoudt D, Alborino D, Haefliger JM, Ott H. Reiter's syndrome after intravesical Bacillus Calmette-Guerin treatment for superficial bladder carcinoma. Br J Rheumatol 1993;32:1096-8.
21. Mouly S, Berenbaum F, Kaplan G. Remitting seronegative symmetrical synovitis with pitting edema following intravesical bacillus Calmette-Guerin instillation. J Rheumatol 2001;28:1699-701.
22. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107:133-44.
23. Nesher G, Ruchlemer E. Alpha-interferon-induced arthritis: clinical presentation, treatment, and prevention. Semin Arthritis Rheum 1998;27:360-5.
24. Altintas A, Alici Y, Melikoglu M, Siva A. Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002;8:534-6.
25. O'Connel PG, Gerber LH, Digiovanna JJ, Peck GL. Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol 1992;19:80-2.
26. Geiger JM, Geiger JM, Saurat JH. Acitretin and etretinate. How and when they should be used. Dermatol Clin 1993;11:117-29.
27. Dubourg G, Koeger AC, Huchet B, Rozenberg S, Bourgeois P. Acute monoarthritis in a patient under isotretinoin. Rev Rhum [Engl Ed] 1996;3:228-9.
28. Leibovitch I, Amital H, Levy Y, Langevitz P, Shoenfeld Y. Isotretinoin-induced adult onset Still's disease. Clin Exp Rheumatol 2000;18:616-8.
29. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991;8:245-9.
30. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 1996;156:1421-5.
31. Gaujard S, Broussolle C, Cathebras P, Dupond JL, Massot C, Ninet J, et al. Lupus érythémateux disséminé survenant après 65 ans. Rev Med Interne 2003;24:288-94.
32. Hess E. Drug-related lupus. N Engl J Med 1988;318:1460-2.
33. Pramatarov KD. Drug-induced lupus erythematosus. Clin Dermatol 1998;16:367-77.
34. Le Goff P, Saraux A. Drug-induced lupus. Rev Rhum [Engl Ed] 1999;66:40-5.
35. Yung RL, Johnson KJ, Richardson BC. Biology of disease. New concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995;73:746-59.
36. Brogan BL, Olsen NJ. Drug-induced rheumatic syndromes. Curr Opin Rheumatol 2003;15:76-80.
37. De Bandt M, Vittecoq O, Descamps V, Le Loët X, Meyer O. Anti-TNF-α induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.
38. Mikuls TR, Moreland LW. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Safety 2003;26:23-32.
39. Price EJ, Venables PJW. Drug-induced lupus. Drug Safety 1995;12:283-90.
40. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991;49:193-280.
41. Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anti-coagulant: absence of thrombosis. Am J Haematol 1988;27:272-5.
42. Asherson RA, Zulman J, Hughes GR. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis 1989;48:232-5.
43. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002;16:765-76.
44. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wess SJ, et al. Treatment of early seropositive rheumatoid arthritis: a two-year double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-41.
45. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol 2001;28:1004-6.
46. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753-5.
47. Calabrese LH, Michel BA, Bloch DA, Arend WP, Edworthy SM, Fau AS, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990;33:1108-13.
48. Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Gonzalez-Gay MA. Hypersensitivity vasculitis in adults: a benign disease usually limited to skin. Clin Exp Rheumatol 2001;19:85-8.
49. Hachulla E. Purpuras vasculaires. Encycl Méd Chir (éditions scientifiques et médicales Elsevier], SAS, Paris, angéiologie, 19-2560 2002:7.
50. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002;36:130-7.
51. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002;41:116-7.
52. Hachulla E. Les urticaires systémiques. Ann Dermatol Venereol 2003;130:1S53-68.
53. Schaffer JV, Davidson DM, McNiff JM, Bolognia JL. Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001;44:198-206.
54. Merkel PA. Drug-induced vasculitis. Rheum Dis Clin North Am 2001;27:849-62.
55. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J 2000;47:467-70.